Evaluation of new therapies for inflammatory bowel disease

Abstract

The pathophysiology of inflammatory bowel disease (IBD) is gradually being unravelled and new therapies are being developed to target the disturbed biological processes. This article outlines the clinical features of IBD, its current therapy and pathogenesis. The difficulties for clinical pharmacologists and gastroenterologists associated with designing, executing and interpreting clinical trials in IBD are then discussed. The final section reviews methods that can used to demonstrate the pharmacological actions of new treatments in patients with IBD. It is emphasized that proof of the therapeutic efficacy of a novel agent with a specific mechanism of action yields not only clinical benefit to patients with IBD, but also indicates the importance of the targeted biochemical pathway in the pathogenesis of the disease.

Figure 1

Abbreviations: IL = interleukin, IFNγ= interferon gamma, TNFα= tumour necrosis factor alpha, ROM = reactive oxygen metabolites, CD = Crohn's disease, UC = ulcerative colitis, ENS = enteric nervous system.